Drug screening model meets cancer organoid technology
Tumor organoids inherit the genomic and molecular characteristics of the donor tumor, which not only bridge the gap between genome and phenotype but also circumvent the disadvantages such as genetic information change by using 2D cell lines and the mouse-specific tumor evolution in patient-derived x...
Main Authors: | Chen Liu, Tianyu Qin, Yuhan Huang, Yuan Li, Gang Chen, Chaoyang Sun |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-11-01
|
Series: | Translational Oncology |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1936523320303326 |
Similar Items
-
Application of Cancer Organoid Model for Drug Screening and Personalized Therapy
by: Jumpei Kondo, et al.
Published: (2019-05-01) -
High-content, targeted RNA-seq screening in organoids for drug discovery in colorectal cancer
by: Maxim Norkin, et al.
Published: (2021-04-01) -
The power and the promise of organoid models for cancer precision medicine with next-generation functional diagnostics and pharmaceutical exploitation
by: Yu-Shui Ma, et al.
Published: (2021-08-01) -
Organoid Models of Glioblastoma and Their Role in Drug Discovery
by: Matthew J. Rybin, et al.
Published: (2021-02-01) -
Patient-Derived Organoids as a Model for Cancer Drug Discovery
by: Colin Rae, et al.
Published: (2021-03-01)